Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French unveil plan to save €350m through greater use of generics

This article was originally published in Scrip

Executive Summary

The French government has unveiled plans to boost the prescribing and dispensing of generic medicines, with a view to making an additional €350m in savings over the next three years. Most of the measures are aimed at healthcare professionals and the public, although the authorities have called on pharmaceutical firms to help by printing the INN more prominently on product packs.

You may also be interested in...



French Campaign To Boost Generics Gets Thumbs Up From European Industry Body

The French health ministry is hoping a new campaign aimed at increasing the use of generics and dispelling any remaining doubts about their quality among the public will bring cost savings.

AbbVie Brings In Non-EU Kaletra To Bolster Dwindling French Supplies

The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.

Russia May Cap Drug Prices In Fight Against COVID-19

As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products. 

Topics

UsernamePublicRestriction

Register

SC028244

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel